2016, Number S1
PDF size: 554.02 Kb.
ABSTRACTThis Consenso Nacional de Hipertensión Arterial Sistémica (National Consensus on Systemic Arterial Hypertension) brings together experiences and joint work of 79 specialists who have been in contact with the patient affected by systemic arterial hypertension. All concepts here presented were outlined on the basis of the real world practice of Mexican hypertensive population. The consensus was developed under strict methodological guidelines. The Delphi technique was applied in two rounds for the development of an appropriate statistical analysis of the concepts exposed by all the specialists, who posed key questions, later developed by the panel of experts of the Hospital de Cardiología, and specialists from the Centro Médico Nacional. Several angles of this illness are shown: detection, diagnosis, pathophysiology, classification, treatment and prevention. The evidence analysis was carried out using PRISMA method. More than 600 articles were reviewed, leaving only the most representative in the references. This document concludes with practical and useful recommendations for the three levels of health care of our country.
US Department of Health and Human Services/ Food and Drug Administration/Center for Drug Evaluation and Research (CDER). Guidance for Industry on Hypertension Indication: Drug Labeling for Cardiovascular Outcome Claims; March, 15, 2011;76 FR 14024:1-12. Disponible en http://www.fda.gov/downloads/ Drugs/.../Guidances/ucm075072.pdf
Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al.; ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-BloodPressure Lowering Arm (ASCOT¬- BPLA): a multicentre randomized controlled trial. Lancet. 2005;366:895-906.